Genesis Molecular AI

Genesis Molecular AI is a technology company applying artificial intelligence to drug design and development. Founded in 2019, it builds foundation models for molecular AI, with a stated focus on unlocking protein targets that have proven difficult for conventional drug discovery. The company operates at the intersection of pharmaceuticals, biotechnology and computational molecular science.

Its work centres on two proprietary products. GEMS (Genesis Exploration of Molecular Space) is the company's platform for molecular AI and drug discovery, covering computational exploration of molecular space. Pearl is a foundation model designed to help scientists identify medicines with high potency and selectivity. Technical domains in use include deep learning, foundation models, protein target modelling and computational molecular exploration.

Genesis Molecular AI has raised over $300M in funding and maintains collaborations with industry leaders including Gilead and Incyte. The team brings together deep learning researchers, software engineers and drug discovery specialists; the exact headcount is not disclosed. The company describes its culture as interdisciplinary, blending AI research with drug discovery expertise, and as driven by a mission to change how drugs are discovered using AI and biotechnology.